These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2519889)

  • 41. Inhibitory effect of esculentoside A on tumour necrosis factor alpha production by human monocytes.
    Wang HB; Fang J; Zheng QY
    Mediators Inflamm; 1996; 5(4):292-4. PubMed ID: 18475742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of esculentoside A on turnour necrosis factor production by mice peritoneal macrophages.
    Jun F; Yue ZQ; Bin WH; Wen JD; Hua YY
    Mediators Inflamm; 1992; 1(6):375-7. PubMed ID: 18475487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Release of adenosine from human neutrophils stimulated by platelet activating factor, leukotriene B(4) and opsonized zymosan.
    Sipka S; Dinya Z; Koltai M; Braquet P; Szegedi G
    Mediators Inflamm; 1992; 1(4):267-71. PubMed ID: 18475472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions between platelet activating factor and eicosanoids during endotoxic shock in anaesthetized pigs.
    Mózes T; Zijlstra FJ; Heiligers JP
    Mediators Inflamm; 1992; 1(3):183-90. PubMed ID: 18475459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokine production by human colonic intraepithelial lymphocytes in controls and ulcerative colitis.
    Hoang P; Dalton HR; de Silv HJ; Jewell DP
    Mediators Inflamm; 1994; 3(3):219-22. PubMed ID: 18472946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes and Relationship of PAF and TNF in Rats with Myocardial Ischaemia and Reperfusion Injury.
    Han YL; Li SH; Zheng QY; Wang HB; Zhang GY; Wu ZG; Chen SC
    Mediators Inflamm; 1994; 3(3):205-9. PubMed ID: 18472943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis.
    Lu YY; Wang CP; Zhou L; Chen Y; Su SH; Feng YY; Yang YP
    World J Gastroenterol; 2008 Feb; 14(5):764-70. PubMed ID: 18205269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.
    Yang Y; Nemoto EM; Harvey SA; Subbotin VM; Gandhi CR
    Gut; 2004 Jun; 53(6):877-83. PubMed ID: 15138217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
    Suputtamongkol Y; Intaranongpai S; Smith MD; Angus B; Chaowagul W; Permpikul C; Simpson JA; Leelarasamee A; Curtis L; White NJ
    Antimicrob Agents Chemother; 2000 Mar; 44(3):693-6. PubMed ID: 10681340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute portal hypertension reflecting shear stress as a trigger of liver regeneration following partial hepatectomy.
    Sato Y; Koyama S; Tsukada K; Hatakeyama K
    Surg Today; 1997; 27(6):518-26. PubMed ID: 9306545
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective.
    Kirkpatrick CJ; Bittinger F; Klein CL; Hauptmann S; Klosterhalfen B
    Virchows Arch; 1996 Feb; 427(5):461-76. PubMed ID: 8624575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacteria induce release of platelet-activating factor (PAF) from polymorphonuclear neutrophil granulocytes: possible role for PAF in pathogenesis of experimentally induced bacterial pneumonia.
    Makristathis A; Stauffer F; Feistauer SM; Georgopoulos A
    Infect Immun; 1993 May; 61(5):1996-2002. PubMed ID: 8478087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience with platelet-activating factor antagonists. Past, present, and near future.
    Guinot P
    Clin Rev Allergy; 1994; 12(4):397-417. PubMed ID: 7743464
    [No Abstract]   [Full Text] [Related]  

  • 54. Platelet-activating factor and the cytokine network in inflammatory processes.
    Bonavida B; Mencia-Huerta JM
    Clin Rev Allergy; 1994; 12(4):381-95. PubMed ID: 7743463
    [No Abstract]   [Full Text] [Related]  

  • 55. New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists.
    Braquet P; Esanu A
    Agents Actions; 1991 Jan; 32(1-2):34-6. PubMed ID: 2058466
    [No Abstract]   [Full Text] [Related]  

  • 56. Involvement of leukotriene B4 and platelet-activating factor in cytokine priming of human polymorphonuclear leucocytes.
    Stewart AG; Harris T; De Nichilo M; Lopez AF
    Immunology; 1991 Feb; 72(2):206-12. PubMed ID: 1849872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PAF. A review of its effects, antagonists and possible future clinical implications (Part II).
    Koltai M; Hosford D; Guinot P; Esanu A; Braquet P
    Drugs; 1991 Aug; 42(2):174-204. PubMed ID: 1717219
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins.
    Braquet P; Hosford D; Koltz P; Guilbaud J; Paubert-Braquet M
    Lipids; 1991 Dec; 26(12):1071-5. PubMed ID: 1668107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Excitable membranes, lipid messengers, and immediate-early genes. Alteration of signal transduction in neuromodulation and neurotrauma.
    Doucet JP; Bazan NG
    Mol Neurobiol; 1992; 6(4):407-24. PubMed ID: 1337456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits.
    Zarco P; Maestre C; Herrero-Beaumont G; González E; Garcia-Hoyo R; Navarro FJ; Braquet P; Egido J
    Clin Exp Immunol; 1992 May; 88(2):318-23. PubMed ID: 1315229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.